AQST Earnings Date: Nov 3, 2026 (Estimated) — Aquestive Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is AQST's next earnings date?
Aquestive Therapeutics, Inc. (AQST) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10 on revenue of $11.0M.
How did AQST do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Aquestive Therapeutics, Inc. posted EPS of -$0.18 versus the -$0.10 estimate, a miss of 50.0%. Revenue was $13.8M against a $11.4M estimate. The stock's 1-day post-earnings move was -4.1%.
How much does AQST stock move after earnings?
AQST beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.2% (up or down) in the day after earnings.
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.10 | -0.18 | -50.00% | $13.8M | ❌ Miss | -4.08% | -2.04% | +13.15% |
| 2026-05-13 | Q1 2026 | -0.13 | -0.07 | +46.15% | $14.4M | ✅ Beat | +14.53% | +0.97% | +0.97% |
| 2026-03-04 | Q4 2025 | -0.12 | -0.15 | -25.00% | $13.0M | ❌ Miss | -2.52% | -2.29% | -5.49% |
| 2025-11-05 | Q3 2025 | -0.12 | -0.14 | -16.67% | $12.8M | ❌ Miss | +2.17% | -7.00% | +6.33% |
| 2025-08-11 | Q2 2025 | -0.18 | -0.14 | +22.22% | $10.0M | ✅ Beat | -2.07% | +8.29% | +26.42% |
| 2025-03-05 | Q4 2024 | -0.13 | -0.19 | -46.15% | $11.9M | ❌ Miss | -7.53% | +5.38% | +2.87% |
| 2024-11-04 | Q3 2024 | -0.13 | -0.13 | +0.00% | $13.5M | ➖ Inline | -7.67% | -1.55% | -16.31% |
| 2024-08-06 | Q2 2024 | -0.12 | -0.03 | +75.00% | $20.1M | ✅ Beat | +0.88% | +15.29% | +24.41% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $13.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Manufacture and Supply Revenue | 86.2% | $11.9M | +24.3% | $18.8M | $7.2M | $9.6M | $11.5M |
| License and Royalty Revenue | 9.6% | $1.3M | +58.0% | $12.1M | $790K | $839K | $1.0M |
| Co-Development and Research Fees | 4.2% | $582K | +54.0% | $1.0M | $418K | $378K | $302K |
By region
Q2 FY26 · $13.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 79.5% | $11.0M | +124.7% | $19.0M | $5.2M | $4.9M | $10.1M |
| Non-US | 20.5% | $2.8M | -44.7% | $13.0M | $3.5M | $5.1M | $2.7M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.